Guillain-Barré Syndrome Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Apr 2018| TMR535A| Transparency

Report Highlights

Guillain–Barré Syndrome Market – Overview

This report on the global Guillain–Barré syndrome market studies the current as well as future prospects of the market globally. Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of products for the treatment of Guillain–Barré syndrome as well as new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. It also provides the overall information and data analysis of the global Guillain–Barré syndrome market with respect to the leading market segments based on therapeutics, route of administration, distribution channel, and geography.

Based on therapeutics, the Guillain–Barré syndrome market has been segmented into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). In terms of route of administration, the market has been classified into oral and parenteral. In terms of distribution channel, the Guillain–Barré syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Each of these segments have been extensively analyzed based on market-related factors such as rates of incidence and prevalence of Guillain–Barré syndrome and available treatment options for Guillain–Barré syndrome. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast (in terms of US$ Mn) for each segment have been provided for the period from 2015 to 2025. The report also provides the compounded annual growth rate (CAGR %) for each segment for the period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the Guillain–Barré syndrome market and that could also influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the degree of competition in the market across different geographies. The scenario of competition among different market players has been evaluated through market share analysis in the competition landscape section of the report. All these factors may help market players to take strategic decisions in order to strengthen their position and increase their share in the global Guillain–Barré syndrome market.

Geographically, the global Guillain–Barré syndrome market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with the respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides the market size and forecast for major countries in the respective region. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s five forces analysis, and market share analysis by key player, thereby presenting a thorough analysis of the overall competition scenario in the global Guillain–Barré syndrome market.

Key players operating in the global Guillain–Barré syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.

The global Guillain–Barré syndrome market has been segmented as follows:

Global Guillain–Barré Syndrome Market, by Therapeutics

Intravenous Immunoglobulin
Plasma Exchange
Others (Analgesics, Anticonvulsants, LMWH, etc.)
Global Guillain–Barré Syndrome Market, by Route of Administration

Oral
Parenteral
 Global Guillain–Barré Syndrome Market, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others (Home Care, Clinics, etc.)
Global Guillain–Barré Syndrome Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.
Rest of Europe
Asia Pacific
ASEAN
India
Japan
China
Rest of Asia Pacific
Rest of World

  • Table 1 : Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
  • Table 2 : Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
  • Table 3 : Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 4 : Global Guillain–Barré Syndrome Market Value (US$ Mn) Forecast, by Region, 2015–2025
  • Table 5 : North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country, 2015–2025
  • Table 6 : North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
  • Table 7 : North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
  • Table 8 : North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 9 : Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 10 : Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
  • Table 11 : Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
  • Table 12 : Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 13 : Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
  • Table 14 : Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
  • Table 15 : Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
  • Table 16 : Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 17 : Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
  • Table 18 : Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
  • Table 19 : Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Figure 1 : Global Guillain–Barré Syndrome Market Snapshot
  • Figure 2 : Global Guillain–Barré Syndrome Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
  • Figure 3 : Global Guillain–Barré Syndrome Market Opportunity Map, 2016
  • Figure 4 : Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
  • Figure 5 : Guillain–Barré Syndrome Market Value Share, by Therapeutics (2016)
  • Figure 6 : Guillain–Barré Syndrome Market Value Share, by Route of Administration (2016)
  • Figure 7 : Guillain–Barré Syndrome Market Value Share, by Distribution Channel (2016)
  • Figure 8 : Key Industry Developments
  • Figure 9 : Key Market Developments
  • Figure 10 : Porter’s Five Forces
  • Figure 11 : Key Success Factors of Top 3 Players
  • Figure 12 : Global Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 13 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Intravenous Immunoglobulin, 2015–2025
  • Figure 14 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Plasma Exchange, 2015–2025
  • Figure 15 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015–2025
  • Figure 16 : Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
  • Figure 17 : Global Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 18 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Oral, 2015–2025
  • Figure 19 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Parenteral, 2015–2025
  • Figure 20 : Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
  • Figure 21 : Global Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 22 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2015–2025
  • Figure 23 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Retail Pharmacies, 2015–2025
  • Figure 24 : Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015–2025
  • Figure 25 : Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 26 : Global Guillain–Barré Syndrome Market Value Share, by Region, 2017 and 2025
  • Figure 27 : Global Guillain–Barré Syndrome Market Attractiveness, by Region, 2017–2025
  • Figure 28 : North America Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
  • Figure 29 : North America Guillain–Barré Syndrome Market Value Share, by Country, 2017 and 2025
  • Figure 30 : North America Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 31 : North America Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 32 : North America Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 33 : North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
  • Figure 34 : North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
  • Figure 35 : North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 36 : North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Country, 2017–2025
  • Figure 37 : Europe Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
  • Figure 38 : Europe Guillain–Barré Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 39 : Europe Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 40 : Europe Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 41 : Europe Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 42 : Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
  • Figure 43 : Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
  • Figure 44 : Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 45 : Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
  • Figure 46 : Asia Pacific Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
  • Figure 47 : Asia Pacific Guillain–Barré Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 48 : Asia Pacific Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 49 : Asia Pacific Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 50 : Asia Pacific Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 51 : Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Therapeutics, 2017–2025
  • Figure 52 : Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Route of Administration, 2017–2025
  • Figure 53 : Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Distribution Channel, 2017–2025
  • Figure 54 : Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Country/Sub-region, 2017–2025
  • Figure 55 : Rest of World Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
  • Figure 56 : Rest of World Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
  • Figure 57 : Rest of World Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
  • Figure 58 : Rest of World Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 59 : Rest of World Guillain–Barré Syndrome Market Attractiveness, by Therapeutics, 2017–2025
  • Figure 60 : Rest of World Guillain–Barré Syndrome Market Attractiveness, by Route of Administration, 2017–2025
  • Figure 61 : Rest of World Guillain–Barré Syndrome Market Attractiveness, by Distribution Channel, 2017–2025
  • Figure 62 : Global Guillain–Barré Syndrome Market Share Analysis, by Company (2016)
  • Figure 63 : Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 64 : Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 65 : Shire plc Breakdown of Net Sales (%), by Geography, 2017
  • Figure 66 : CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 67 : CSL Behring LLC Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 68 : CSL Behring LLC Breakdown of Net Sales (%), by Geography, 2016
  • Figure 69 : Grifols, S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 70 : Grifols, S.A. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 71 : Grifols, S.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 72 : Octapharma AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 73 : Octapharma AG: R&D Expenses (US$ Mn), 2014–2017
  • Figure 74 : Nihon Pharmaceutical Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 75 : Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 76 : Takeda Pharmaceutical Company Limited Breakdown of Ethical Drugs: Revenue (%), by Region, 2016
  • Figure 77 : China Biologic Products Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 78 : China Biologic Products Holdings, Inc. Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 79 : Biotest AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 80 : Biotest AG Breakdown of Net Sales (%), by Region, 2016
  • Figure 81 : Biotest AG Breakdown of Net Sales (%), by Business Segment, 2016
  • Figure 82 : Kedrion S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 83 : Kedrion S.p.A. Breakdown of Net Sales (%), by Region, 2016
  • Figure 84 : Kedrion S.p.A. Breakdown of Net Sales (%), by Business Segment, 2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report